**WARNINGS AND PRECAUTIONS**

- Serotonin syndrome has been reported with cyclobenzaprine when used in combination with other serotonergic drugs (5.1).
- Cylobenzaprine is structurally related to tricyclic antidepressants which have been reported to produce adverse cardiovascular effects or CNS depressant effects (5.2).
- Use in the elderly is not recommended (5.3).
- Use in patients with hepatic impairment is not recommended (5.4).
- Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intracranial pressure and in patients taking anticholinergic medications (5.5).

**ADVERSE REACTIONS**

Most common adverse reactions (incidence ≥3% in any treatment group and greater than placebo): dry mouth, dizziness, fatigue, constipation, nausea, dyspepsia, and somnolence (6).

To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**DRUG INTERACTIONS**

- MAO Inhibitors: Life-threatening interactions may occur (4, 7).
- Serotonergic Drugs: Serotonin syndrome has been reported (5.1, 7).
- CNS Depressants: Effects of alcohol, barbiturates, and other CNS depressants may be enhanced (5.2, 7).
- Tramadol: Seizure risk may be enhanced (7).
- Guanethidine: Antihypertensive effect may be blocked (7).

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 5/2020
AMRIX® (cyclobenzaprine hydrochloride extended-release capsules)

verapamil, or MAO inhibitors. The concomitant use of AMRIX with MAO inhibitors is contraindicated [see Contraindications (4)]. Serotonin syndrome symptoms may include mental status changes (e.g., confusion, agitation, hallucinations), autonomic instability (e.g., diaphoresis, tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g., tremor, ataxia, hyperreflexia, clonus, muscle rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Treatment with AMRIX may be associated with a life-threatening serotonin syndrome and should be discontinued immediately if the above reactions occur and supportive symptomatic treatment should be initiated. If concomitant treatment with AMRIX and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases.

5.2 Tricyclic Antidepressant-like Effects
Cyclobenzaprine is structurally related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke [see Contraindications (4)]. AMRIX may enhance the effects of alcohol, barbiturates, and other CNS depressants. Some of the more serious central nervous system (CNS) reactions noted with the tricyclic antidepressants have occurred in short-term studies of cyclobenzaprine for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm. If clinically significant CNS symptoms develop, consider discontinuation of AMRIX.

6.1 Clinical Trials Experience

6.2 Postmarketing Experience
The following adverse reactions have been reported in clinical studies or postmarketing experience with AMRIX, cyclobenzaprine IR, or tricyclic drugs. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

In a postmarketing surveillance program of cyclobenzaprine IR, the adverse reactions reported most frequently were drowsiness, dry mouth, and dizziness and adverse reactions reported in 1% to 3% of the patients were: fatigue/tiredness, asthenia, nausea, constipation, dyspepsia, unpleasant taste, blurred vision, headache, nervousness, and confusion.

The following adverse reactions have been reported in postmarketing experience (AMRIX or cyclobenzaprine IR), in clinical studies of cyclobenzaprine IR (incidence <1%), or in postmarketing experience with other tricyclic drugs:

- Body as a Whole: Syncope; chest pain; edema.
- Cardiovascular: Tachycardia; arrhythmia; vasodilatation; palpitation; hypotension; hypertension; myocardial infarction; heart block; stroke.
- Digestive: Vomiting; anorexia; diarrhea; gastrointestinal pain; gastritis; thirst; flatulence; edema of the tongue; abnormal liver function and rare reports of hepatitis, jaundice, and cholestasis; paralytic ileus; tongue discoloration; stomatitis; parotid swelling.
- Endocrine: Inappropriate ADH syndrome.
- Hematologic and Lymphatic: Purpura; bone marrow depression; leukopenia; eosinophilia; thrombocytopenia.
- Hypersensitivity: Anaphylaxis; angioedema; pruritus; facial edema; urticaria; rash.
- Metabolic, Nutritional, and Immune: Elevation and lowering of blood sugar levels; weight gain or loss.
- Musculoskeletal: Local weakness; myalgia.
- Nervous System and Psychiatric: Seizures; ataxia; vertigo; dysarthria; tremors; hypertonia; convulsions; muscle twitching; disorientation; insomnia; depressed mood; abnormal sensations; anxiety; agitation; psychosis; abnormal thinking and dreaming; hallucinations; excitement; paresthesia; diplopia; serotonin syndrome; neuroleptic malignant syndrome; decreased or increased libido; abnormal gait; delusions; aggressive behavior; paranoia; peripheral neuropathy; Bell’s palsy; alteration in EEG patterns; extrapyramidal symptoms.
- Respiratory: Dyspnea.
- Skin: Sweating; photosensitization; alopecia.
- Special Senses: Ageusia; tinnitus.
- Urinary: Urinary frequency and/or retention; impaired urination; dilation of urinary tract; impotence; testicular swelling; gynecomastia; breast enlargement; galactorrhea.

7 DRUG INTERACTIONS
Based on its structural similarity to tricyclic antidepressants, AMRIX may have life-threatening interactions with MAO inhibitors [see Contraindications (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants. Use of AMRIX may enhance the seizure risk in patients taking tramadol, or may block the antidepressant effects of guanethidine and similarly acting compounds.

Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [see Warnings and Precautions (5.1)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary
Available data from case reports with AMRIX use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In rats, decreased pup body weight and survival was noted at cyclobenzaprine doses ≥10 mg/kg/day (approximately 3 times the maximum recommended human dose (MRHD) of 30 mg/day), when administered orally during pregnancy and lactation (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data
Animal Data

No adverse embryofetal effects were reported following oral administration of cyclobenzaprine during organogenesis to mice and rabbits at maternal doses up to 20 mg/kg/day (approximately 3 and 15 times the MRHD, respectively, on a mg/m² basis). Maternal toxicity characterized by decreased body weight gain was observed only in mice at the highest tested dose of 20 mg/kg/day. Decreased pup body weight and survival were reported in a prenatal and postnatal study where pregnant rats were treated orally with cyclobenzaprine during pregnancy and lactation with maternal doses of 10 and 20 mg/kg/day (approximately 3 and 6 times the MRHD on a mg/m² basis). Maternal toxicity, characterized by a decreased body weight gain, was observed only at the highest tested dose of 20 mg/kg/day.

8.2 Lactation

Risk Summary
There are no data on the presence of cyclobenzaprine in either human or animal milk, the effects on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for AMRIX and any potential adverse effects on the breastfed child from AMRIX or from the underlying maternal condition.

8.4 Pediatric Use

Safety and effectiveness of AMRIX have not been studied in pediatric patients.

8.5 Geriatric Use
Clinical studies of AMRIX did not include sufficient numbers of patients aged 65 and over to determine the safety and efficacy of AMRIX in the elderly population.

The plasma concentration and half-life of cyclobenzaprine are substantially increased in the elderly when compared to the general patient population. Accordingly, use of AMRIX is not recommended in the elderly [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].

Table 1: Incidence of the Most Common Adverse Reactions Occurring in ≥ 3% of Patients in Any Treatment Group and Greater Than Placebo in the Two Phase 3, Double-Blind AMRIX Trials

<table>
<thead>
<tr>
<th>Placebo</th>
<th>AMRIX 15 mg</th>
<th>AMRIX 30 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=128</td>
<td>N=127</td>
<td>N=126</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>2%</td>
<td>6%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2%</td>
<td>3%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>2%</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>0%</td>
<td>1%</td>
</tr>
<tr>
<td>Somnolence</td>
<td>0%</td>
<td>1%</td>
</tr>
<tr>
<td>Nausea</td>
<td>1%</td>
<td>3%</td>
</tr>
<tr>
<td>Dysepsia</td>
<td>1%</td>
<td>0%</td>
</tr>
</tbody>
</table>

*AMRIX 15 mg QD, AMRIX 30 mg QD, or cyclobenzaprine IR tablets TID

2
AMRIX® (cyclobenzaprine hydrochloride extended-release capsules)

8.6 Hepatic Impairment

The use of AMRIX is not recommended in patients with mild, moderate, or severe hepatic impairment [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.3 Dependence

Pharmacologic similarities among the tricyclic drugs require that certain withdrawal symptoms be considered when AMRIX is administered, even though they have not been reported to occur with this drug. Abrupt cessation of treatment after prolonged administration rarely may produce nausea, headache, and malaise. These are not indicators of addiction.

10 OVERDOSAGE

10.1 Manifestations

Although rare, deaths may occur from overdose with AMRIX. Multiple drug ingestion (including alcohol) is common in deliberate cyclobenzaprine overdose. As management of overdose is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. Signs and symptoms of toxicity may develop rapidly after cyclobenzaprine overdose; therefore, hospital monitoring is required as soon as possible.

The most common effects associated with cyclobenzaprine overdose are drowsiness and tachycardia. Less frequent manifestations include tremor, agitation, coma, ataxia, hypertension, slurred speech, confusion, dizziness, nausea, vomiting, and hallucinations. Rare but potentially critical manifestations of overdose are cardiac arrest, chest pain, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of cyclobenzaprine toxicity. Other potential effects of overdose include any of the symptoms listed under Adverse Reactions.

10.2 Management

General

As management of overdose is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. In order to protect the physician from the rare but potentially critical manifestations described above, obtain an ECG and immediately initiate cardiac monitoring. Protect the patient’s airway, establish an intravenous line, and initiate gastric decontamination. Observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. Monitoring of plasma drug levels should not guide management of the patient. Dialysis is probably of no value because of low plasma concentrations of the drug.

Gastrointestinal Decontamination

All patients suspected of an overdose with AMRIX should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage and emesis is contraindicated.

Cardiovascular

A maximal limb-lead QRS duration of 0.10 seconds may be the best indication of the severity of the overdose. Serum alkalization to a pH of 7.45 to 7.55, using intravenous sodium bicarbonate and hyperventilation (as needed), should be the severity of the overdose. Serum alkalinization, to a pH of 7.45 to 7.55, using intravenous sodium bicarbonate and hyperventilation (as needed), should be instituted for patients with dysrhythmias and/or QRS widening. A pH >7.60 or a maximal limb-lead QRS duration of 0.10 seconds may be the best indication of cyclobenzaprine toxicity.

In patients with CNS depression, early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in close consultation with a poison control center.

Psychiatric Follow-Up

Since overdose is often deliberate, patients may attempt suicide by other means during the recovery phase. Psychiatric referral may be appropriate.

Pediatric Management

The principles of management of child and adult overdose are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.

11 DESCRIPTION

AMRIX is a skeletal muscle relaxant which relieves muscle spasm of local origin without interfering with muscle function. The active ingredient in AMRIX extended-release capsules is cyclobenzaprine hydrochloride. USP. Cyclobenzaprine hydrochloride (HCl) is a white, crystalline tricyclic amine salt with the empirical formula \( \text{C}_{20}\text{H}_{21}\text{N} \cdot \text{HCl} \) and a molecular weight of 311.9. It has a melting point of 217°C, and a pKₐ of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-[5(5H-Dibenzo-

AMRIX extended-release capsules for oral administration are supplied in 15 and 30 mg strengths. AMRIX capsules contain the following inactive ingredients: diethyl phthalate NF, ethylcellulose NF (Ethocel Standard 10 Premium), gelatin, Opadry® Clear YS-1-7006, sugar spheres NF (20-25 mesh), and titanium dioxide. AMRIX 15 mg capsules also contain D&C yellow #10, FD&C green #3, and FD&C red #40. AMRIX 30 mg capsules also contain FD&C blue #1, FD&C blue #2, and FD&C red #40, and FD&C yellow #6.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Cyclobenzaprine has not been shown to be effective in muscle spasm due to central nervous system disease. In animal models, cyclobenzaprine reduced or abolished skeletal muscle hyperactivity. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or directly on skeletal muscle. Such studies show that cyclobenzaprine acts primarily within the central nervous system at the brain stem as opposed to the spinal cord level, although an overlapping action on the latter may contribute to its overall skeletal muscle relaxant activity. Evidence suggests that the net effect of cyclobenzaprine is a reduction of tonic somatic motor activity, influencing both gamma (\( \gamma \)) and alpha (\( \alpha \)) motor systems. Pharmacological studies in animals demonstrated a similarity between the effects of cyclobenzaprine and the structurally related tricyclic antidepressants, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation. Cyclobenzaprine caused slight to moderate increase in heart rate in animals.

12.2 Pharmacokinetics

Absorption

Following single-dose administration of AMRIX 15 mg and 30 mg in healthy adult subjects (n=15), \( C_{max} \), AUC₀₋∞ and AUC₀₋168h increased in an approximately dose-proportional manner from 15 mg to 30 mg. The time to peak plasma cyclobenzaprine concentration (\( T_{max} \)) was 7 to 8 hours for both doses of AMRIX.

In a pharmacokinetic study of immediate-release cyclobenzaprine in 16 subjects (n=15) utilizing a single dose of AMRIX 30 mg demonstrated a statistically significant increase in bioavailability when AMRIX 30 mg was given with food relative to the fasted state. There was a 35% increase in peak plasma cyclobenzaprine concentration (\( C_{max} \)) and a 20% increase in exposure (AUC₀₋∞ and AUC₀₋168h) in the presence of food. No effect, however, was noted in the shape of the mean plasma drug concentration versus time profile. Cyclobenzaprine in plasma was first detectable in both the fed and fasted states at 1.5 hours.

In a multiple-dose study utilizing AMRIX 30 mg administered once daily for 7 days in a group of healthy adult subjects (n=35), a 2.5-fold accumulation of plasma cyclobenzaprine levels was noted at steady-state.

Metabolism and Excretion

Cyclobenzaprine is extensively metabolized and is excreted primarily as glucuronides via the kidney. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate the effects of cyclobenzaprine and the structurally related tricyclic antidepressants, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation. Cyclobenzaprine caused slight to moderate increase in heart rate in animals.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies were conducted in CD-1 mice and Sprague-Dawley rats with oral cyclobenzaprine to evaluate its carcinogenic potential. In an 81-week carcinogenicity study, metastatic hemangiosarcoma was seen in 3 of 21 male mice at 10 mg/kg/day (approximately 2 times the maximum recommended human dose (MRHD) of 30 mg/dg on a mg/m² basis). In a 105-week carcinogenicity study, malignant astrocytoma was seen in 3 of 50 male rats at 10 mg/kg/day (approximately 3 times the MRHD on a mg/m² basis). There were no tumor findings in female mice or rats.
AMRIX® (cyclobenzaprine hydrochloride extended-release capsules)

**Mutagenesis**
Cyclobenzaprine HCl was not mutagenic or clastogenic in the following assays: an in vitro Ames bacterial mutation assay, in vitro Chinese hamster ovary (CHO) cell chromosomal aberration test, and in vivo mouse bone marrow micronucleus assay.

**Impairment of Fertility**
Cyclobenzaprine HCl, when administered 70 and 14 days prior to mating to male and female rats, respectively, had no effects on fertility or reproductive performance at oral doses up to 20 mg/kg/day (approximately 6.5 times the MRHD on a mg/m² basis).

**13.2 Animal Toxicology and/or Pharmacology**
In a 67-week study with rats that received cyclobenzaprine at oral doses of 10, 20, or 40 mg/kg/day (3 to 15 times the MRHD on mg/m² basis), there were findings in the liver consisting of midzonal vacuolation with lipidosis for males and midzonal and centrilobular hepatocytic enlargement for females. In addition, there were findings of centrilobular coagulative necrosis. In the higher dose groups, these microscopic changes were seen after 26 weeks and even earlier in rats that died prior to 26 weeks; at lower doses, these changes were not seen until after 26 weeks. In a 26-week study with Cynomolgus monkeys that received cyclobenzaprine at oral doses of 2.5, 5, 10, or 20 mg/kg/day, one monkey at 20 mg/kg/day (15 times the MRHD on mg/m² basis) was euthanized in week 17. Morbidity for this animal was attributed to findings of chronic pancreatitis, cholecystitis, cholangitis, and focal liver necrosis.

**14 CLINICAL STUDIES**
Efficacy was assessed in two double-blind, parallel-group, active-controlled, placebo-controlled studies of identical design of AMRIX 15 mg and 30 mg taken once daily, between 6:00 and 7:00 PM, cyclobenzaprine 10 mg three times a day, or placebo for 14 days in patients with muscle spasms associated with acute painful musculoskeletal conditions.

There were significant differences in the primary efficacy analysis, the patient's rating of medication helpfulness, between the AMRIX 15 mg group and the placebo group at Days 4 and 14 in one study and between the AMRIX 30 mg group and the placebo group at Day 4 in the second study.

**Table 2: Patients’ Rating of Medication Helpfulness - Study 1**

<table>
<thead>
<tr>
<th></th>
<th>Day 4</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of Patients (%)</td>
<td>Number of Patients (%)</td>
<td>Number of Patients (%)</td>
</tr>
<tr>
<td>Placebo (N = 64)</td>
<td>Placebo (N = 64)</td>
<td>AMRIX 30 mg (N = 64)</td>
<td>AMRIX 30 mg (N = 64)</td>
</tr>
<tr>
<td>Excellent</td>
<td>1 (2%)</td>
<td>3 (5%)</td>
<td>12 (19%)</td>
</tr>
<tr>
<td>Very Good</td>
<td>5 (8%)</td>
<td>13 (20%)</td>
<td>9 (14%)</td>
</tr>
<tr>
<td>Good</td>
<td>15 (23%)</td>
<td>22 (34%)</td>
<td>10 (16%)</td>
</tr>
<tr>
<td>Fair</td>
<td>24 (38%)</td>
<td>20 (31%)</td>
<td>16 (25%)</td>
</tr>
<tr>
<td>Poor</td>
<td>10 (16%)</td>
<td>5 (8%)</td>
<td>9 (14%)</td>
</tr>
<tr>
<td>Missing</td>
<td>9 (14%)</td>
<td>1 (2%)</td>
<td>8 (13%)</td>
</tr>
</tbody>
</table>

*p Percentages are rounded to the nearest whole percent.

**Table 3: Patients’ Rating of Medication Helpfulness - Study 2**

<table>
<thead>
<tr>
<th></th>
<th>Day 4</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of Patients (%)</td>
<td>Number of Patients (%)</td>
<td>Number of Patients (%)</td>
</tr>
<tr>
<td>Placebo (N = 64)</td>
<td>Placebo (N = 64)</td>
<td>AMRIX 15 mg (N = 63)</td>
<td>AMRIX 15 mg (N = 63)</td>
</tr>
<tr>
<td>Excellent</td>
<td>1 (2%)</td>
<td>2 (3%)</td>
<td>10 (16%)</td>
</tr>
<tr>
<td>Very Good</td>
<td>10 (16%)</td>
<td>12 (19%)</td>
<td>12 (19%)</td>
</tr>
<tr>
<td>Good</td>
<td>14 (22%)</td>
<td>21 (33%)</td>
<td>13 (20%)</td>
</tr>
<tr>
<td>Fair</td>
<td>16 (25%)</td>
<td>17 (27%)</td>
<td>14 (22%)</td>
</tr>
<tr>
<td>Poor</td>
<td>19 (30%)</td>
<td>6 (10%)</td>
<td>12 (19%)</td>
</tr>
<tr>
<td>Missing</td>
<td>4 (6%)</td>
<td>5 (8%)</td>
<td>3 (5%)</td>
</tr>
</tbody>
</table>

*p Percentages are rounded to the nearest whole percent.

In addition, one of the two studies demonstrated significant differences between the AMRIX 30 mg group and the placebo group in terms of patient-rated relief from local pain due to muscle spasm at Day 4 and Day 8, in patient-rated restriction of movement at Day 4 and Day 8, and in patient-rated global impression of change at Day 4, Day 8, and Day 14. In both studies, there were no significant treatment differences between the AMRIX treatment groups and the placebo group in physician’s global assessment, patient-rated restriction in activities of daily living, or quality of nighttime sleep.

**16 HOW SUPPLIED/STORAGE AND HANDLING**

**16.1 How Supplied**
AMRIX extended-release capsules are available in 15 and 30 mg strengths, packaged in bottles of 60 capsules. AMRIX 15 mg capsules (NDC 63459-700-60) are orange/orange and are embossed in blue ink with “15 mg” on the body, and Cephalon “C” logo, “Cephalon”, and a dashed band on the cap. AMRIX 30 mg capsules (NDC 63459-701-60) are blue/red and are embossed in white ink with “30 mg” on the body, and Cephalon “C” logo, “Cephalon”, and a dashed band on the cap.

**16.2 Storage and Handling**
Dispense in a tight, light-resistant container as defined in the USP/NF.

**PATIENT INFORMATION**

**AMRIX® (am-rix)**
(cyclobenzaprine hydrochloride extended-release capsules)

**What is AMRIX?**
AMRIX is a prescription medicine used along with rest and physical therapy to help treat muscle spasm due to acute, painful musculoskeletal problems.

AMRIX should only be used for up to 2 or 3 weeks. It is not known if AMRIX is effective when used for longer periods. It is not known if AMRIX is safe and effective in children.

**Do not take AMRIX if you:**
- are allergic to cyclobenzaprine or any of the ingredients in AMRIX. See the end of this Patient Information leaflet for a complete list of ingredients in AMRIX.
- have had a recent heart attack
- have heart rhythm problems (arrhythmias)
- have heart failure
- have an overactive thyroid (hyperthyroidism)

Talk to your healthcare provider or get medical help right away if you have symptoms of an allergic reaction such as:
- difficulty breathing
- hives
- swelling of your face or tongue
- itching
- are taking certain antidepressants, known as monoamine oxidase (MAO) inhibitors or it has been 14 days or less since you stopped taking a MAO inhibitor. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.

**continued**
Before taking AMRIX, tell your healthcare provider about all of your medical conditions, including if you:
• have a history of eye problems including glaucoma
• have heart problems or have had a heart attack
• have liver problems
• have trouble emptying your bladder (urinary retention)
• are pregnant or plan to become pregnant. It is not known if AMRIX will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if AMRIX passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take AMRIX.

Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take:
• a medicine to treat depression, mood, anxiety, psychotic, or thought disorders
• a pain medicine called tramadol or meperidine
• barbiturates or other medicines that depress your central nervous system (CNS depressants)
• a medicine that prevents nerve impulses (anticholinergic medicines)
• a medicine to help quit smoking called bupropion
• a blood pressure medicine called verapamil

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider or pharmacist when you get a new medicine.

How should I take AMRIX?
• Take AMRIX exactly as your healthcare provider tells you to take it.
• Your healthcare provider will tell you how much AMRIX to take and when to take it.
• Your healthcare provider may change your AMRIX dose if needed.
• Take AMRIX around the same time every day.
• Swallow AMRIX capsules whole.
• If you have difficulty swallowing AMRIX capsules, tell your healthcare provider. Your healthcare provider may recommend opening the AMRIX capsule and mixing the contents with applesauce.
• AMRIX should only be taken for short periods (up to two or three weeks).
• If you take too much AMRIX, call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking AMRIX?
You should not drink alcohol until you know how AMRIX affects you. Taking AMRIX with alcohol or other medicines that depress your central nervous system can slow your thinking and physical response times.
Do not drive, operate machinery, or do other dangerous activities until you know how AMRIX affects you.

What are the possible side effects of AMRIX?
AMRIX may cause serious side effects, including:
• Serotonin syndrome is a serious medical condition that may happen when AMRIX is taken with certain other medicines. Call your healthcare provider right away or go to the nearest hospital emergency room if you have some or all of these symptoms suggestive of serotonin syndrome:
  ◦ agitation, hallucinations, coma, or other changes in mental status
  ◦ coordination problems or muscle twitching (overactive reflexes)
  ◦ fast heartbeat, high or low blood pressure
  ◦ sweating or fever
  ◦ nausea, vomiting, or diarrhea
  ◦ muscle stiffness or tightness
• AMRIX may cause serious side effects that may lead to heart attack or stroke. Call your healthcare provider right away or go to the nearest hospital emergency room if you have:
  • irregular or abnormal heartbeats (arrhythmias)
  • fast heartbeat (tachycardia)

The most common side effects of AMRIX include:
• dry mouth
• nausea
• dizziness
• upset stomach
• fatigue
• drowsiness
• constipation

These are not all the possible side effects of AMRIX. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store AMRIX?
• Store AMRIX at room temperature between 68°F to 77°F (20°C to 25°C).
• Keep AMRIX in a tightly closed container, and keep AMRIX out of light.
• Keep AMRIX and all medicines out of the reach of children.

General information about the safe and effective use of AMRIX.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use AMRIX for a condition for which it was not prescribed. Do not give AMRIX to other people, even if they have the same symptoms you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about AMRIX that is written for healthcare professionals.

What are the ingredients in AMRIX?
Active Ingredient: cyclobenzaprine hydrochloride USP
Inactive Ingredients: diethyl phthalate NF, ethylcellulose NF (Ethocel Standard 10 Premium), gelatin, Opadry® Clear YS-1-7006, sugar spheres NF (20-25 mesh), and titanium dioxide.
AMRIX 15 mg capsules also contain: D&C yellow #10, FD&C green #3, and FD&C red #40.
AMRIX 30 mg capsules also contain: FD&C blue #1, FD&C blue #2, FD&C red #40, and FD&C yellow #6.

Distributed By:
Teva Pharmaceuticals USA, Inc.
Parsippany, NJ 07054
Manufactured By:
Adare Pharmaceuticals, Inc.
Vandalia, OH 45377
AMRPL-006
For more information, go to www.AMRIX.com or call 1-888-483-8279.
© 2020 Teva Pharmaceuticals USA, Inc.
All rights reserved.

This Patient Information has been approved by the U.S. Food and Drug Administration Revised: May 2020

continued
INSTRUCTIONS FOR USE

AMRIX® (cyclobenzaprine hydrochloride extended-release capsules)

Read this Instructions for Use before you prepare your first dose of AMRIX® (cyclobenzaprine hydrochloride extended-release capsules) mixed with applesauce using the capsule sprinkle method, each time you get a refill, and as needed. There may be new information. Ask your healthcare provider or pharmacist if you have any questions about how to mix or give a dose of AMRIX® using the capsule sprinkle method.

Important Information:
• Do not chew AMRIX® capsules or the granules that are in the capsules.
• The capsule sprinkle method for mixing the contents of AMRIX® capsules with applesauce may be used for adults who cannot swallow capsules. **Do not use any other food in the place of applesauce.**

Preparing a dose of AMRIX® using the capsule sprinkle method.

Before you prepare a dose of AMRIX® mixed with applesauce using the capsule sprinkle method, gather the following supplies:
- paper towels
- tablespoon
- applesauce
- cup of water

Step 1: Choose a clean, flat work surface. Place a clean paper towel on the work surface. Then place the other supplies on the paper towel.

Step 2: Wash and dry your hands well.

Step 3: Check the dose that was prescribed by your healthcare provider. Take out the number of AMRIX® capsules needed to prepare your dose. Place them on the paper towel.

Step 4: Place enough applesauce to fill your tablespoon. Set the tablespoon down on the paper towel.

Step 5: Hold the AMRIX® capsule in an upright position (vertical) directly over the tablespoon. Hold each end of the AMRIX® capsule between your thumbs and index (pointer) fingers.

Step 6: Carefully twist both ends of the AMRIX® capsule in opposite directions to open it. Be careful not to spill the capsule contents.

Step 7: Sprinkle the contents of the AMRIX® capsule onto the applesauce.
  • Check the capsule shells to make sure they are empty.
  • Throw away the empty capsule shells.

If the total prescribed dose is more than 1 capsule, repeat Steps 5 through 7 for each capsule. Do not add more applesauce. Then follow the rest of the steps below.

Step 8: Pick up the tablespoon and swallow the AMRIX® capsule contents and applesauce mixture right away. **Do not chew the AMRIX® capsule contents and applesauce mixture.**

Step 9: Rinse your mouth with a sip of water and swallow to make sure that all of the AMRIX® granules have been swallowed.

Step 10: Throw away any unused AMRIX® capsule content and applesauce mixture. Do not keep any AMRIX® capsule content and applesauce mixture for future use.

How should I store AMRIX®?
• Store AMRIX® capsules at room temperature between 68°F to 77°F (20°C to 25°C).

Keep AMRIX® capsules and all medicines out of the reach of children.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

AMRIFU-001
Issued: April 2019

teva
AMR-40624